ClinicalTrials.gg
Not yet recruitingNCT06746675HFPTUpdated Oct 26, 2026

Evaluating the Healthy Families PrEP Program for Women at Risk for HIV

An interventional study of Healthy Families PrEP Counselling Intervention in HIV, Pregnancy and Pre-Exposure Prophylaxis of HIV Infection, sponsored by Yale University. Not yet recruiting at 1 site in Uganda. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Yale University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 26, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in HIV Infections by Yale University — 2 open to participants now, 3 under way, none of them phase 3. HIV Infections · Yale University.

Planned enrollment
5th of 27
660 · median 60
Started
2026
with 1 other
No phase
15 of 30
1 open now
Registered
30th of 30
by date

Among the 30 studies in HIV Infections by Yale University, this one is the 5th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 30th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 30 studies in HIV Infections by Yale University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in HIV Infections by Yale University, or all of them as a file.
02

Study summary

Study investigators developed and piloted a counselling intervention, Healthy Families-PrEP, that supports women to use HIV prevention strategies while trying for and during pregnancy. They will now adapt the intervention to community clinics and postpartum women and test the intervention. The goal is to reduce HIV incidence among women and children.

Read the detailed description

Women in Uganda who are planning for pregnancy, pregnant, or postpartum and have a partner living with HIV are vulnerable to acquiring HIV.

Adapting this intervention to community clinics and testing effectiveness aligns with global and Ugandan Ministry of Health goals to reduce HIV incidence among women of reproductive age and eliminate perinatal transmission. Additionally, costing analyses will be conducted to determine the cost of implementing HF-PrEP from both payer and societal perspectives. This work will inform future intervention implementation.

03

Conditions studied

  • HIV
  • Pregnancy
  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

Keywords

  • HIV
  • pregnancy
  • Pre-exposure prophylaxis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤45 years
  • Willing and able to participate in the process
  • -uninfected by self-report, but have indications for HIV prevention strategies, such as having a partner living with HIV or who they think may be living with HIV
  • Reporting pregnancy in the past 2 years, and/or desire to have a child in the next year, and/or have a partner who desires to a child in the next year
  • Fluent in English or local language
  • Living within 60km of a healthcare center included in the trial
  • HIV Negative (onsite rapid testing)

Exclusion criteria

Exclusion Criteria:

  • Not reporting pregnancy in the past 2 years
  • Does not report personal or partner desire to have a child in the next year
  • Not willing to provide
  • Not able to communicate in English or local language
  • Does not report pregnancy in the past 2 years and/or does not report personal or partner desire to have a child in the next year
  • Not able to communicate in English or local language
  • Living beyond 60km of the trial healthcare center
  • -positive (onsite rapid testing)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (estimated)

Study arms

  • Active comparator
    Healthy Families PrEP Counselling Intervention

    Intervention Health Care Centers will offer the guideline-based PrEP standard of care plus trained staff will conduct the 3-session Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV.

    Drug: Healthy Families PrEP Counselling Intervention

  • No intervention
    Standard of care PrEP services for perinatal women

Interventions

  • DrugHealthy Families PrEP Counselling Intervention

    Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV. Session 1 focuses on providing information about HIV prevention in the context of reproductive goals (using tools with locally developed images), increasing motivation for behavior change, and developing a safer conception plan (e.g., PrEP uptake, PrEP adherence, couples-based counselling and testing, delaying condomless sex until partner serostatus known and, if living with HIV, virally suppressed). Sessions 2 and 3 (conducted at 1 and 3 months) review the safer conception plan and revise as needed (e.g., changes in readiness to initiate PrEP, partner serostatus knowledge) and engaging in problem-solving barriers (including structural) to plan execution, communication skills training, and motivational strategies for successful plan execution. Participants receive quarterly adherence counseling using tools developed by this team.

06

What researchers measure

Primary outcomes

  1. PrEP initiation - Women who start to use PrEP

    The primary effectiveness outcome will be proportion of women at 6 months with intracellular TFV-DP concentration consistent with taking at least 4 doses per week.

    Time frame: Enrolment to 6 months

Secondary outcomes

  1. Women who continue to use PrEP when they become pregnant

    Investigators will explore secondary outcomes of PrEP adherence patterns over perinatal periods with quarterly blood draws for TFV measurements

    Time frame: Enrolment to 18 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2031, 49 months later.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 49 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Jan 2031
CompletionEst.
Jan 2032
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Dec 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Aug 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06746675
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Dec 2026 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Jan 2032 (estimated)
Last update
Oct 26, 2026

Study contacts

Lynn T Matthews, MD, MPH
Contact
lynn.matthews@yale.edu
617-650-5257
Patricia M Smith, MSc
Contact
pmsmith@uabmc.edu
9024395214
Lynn T Matthews, MD, MPH
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion